Tiago Biachi, MD, PhD, emphasizes that biosimilars are vital for reducing financial toxicity and ensuring equitable, affordable access to advanced treatments in gastrointestinal (GI) cancer care, ...

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with ...

Number 4: The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to ...

The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective ...

The top 5 rheumatology biosimilar articles of 2024 highlight significant FDA approvals, including high-concentration adalimumab and tocilizumab biosimilars, along with evidence supporting the safety ...

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most popular podcast episodes of the year. The top 5 podcast episodes of the year ...

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, ...